Celyad SA (NASDAQ:CYAD) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $74.00 for the company, according to Zacks. Zacks has also assigned Celyad an industry rank of 191 out of 265 based on the ratings given to related companies.
Separately, ValuEngine lowered shares of Celyad from a “hold” rating to a “sell” rating in a report on Friday, December 1st.
Institutional investors and hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. grew its holdings in Celyad by 36.5% during the 4th quarter. Victory Capital Management Inc. now owns 443,902 shares of the company’s stock valued at $19,483,000 after buying an additional 118,590 shares in the last quarter. Deutsche Bank AG purchased a new position in shares of Celyad in the fourth quarter valued at $150,000. Renaissance Technologies LLC purchased a new position in shares of Celyad in the fourth quarter valued at $227,000. Finally, Jane Street Group LLC purchased a new position in shares of Celyad in the fourth quarter valued at $260,000. 4.73% of the stock is owned by institutional investors and hedge funds.
Shares of Celyad (CYAD) opened at $37.52 on Friday. Celyad has a fifty-two week low of $20.51 and a fifty-two week high of $64.75.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://ledgergazette.com/2018/03/20/celyad-sa-cyad-given-74-00-consensus-price-target-by-analysts.html.
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celyad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad and related companies with MarketBeat.com's FREE daily email newsletter.